Univariate analysis of enhancer of zeste homolog 2 (EZH2) expression and various clinicopathological parameters in 338 patients with primary hepatocellular carcinoma
Variable | Testing cohort | Validation cohort | ||||
All cases | HR (95% CI) | p value* | All cases | HR (95% CI) | p Value* | |
Age (years) | 0.627 | 0.721 | ||||
≤47.9† | 105 | 1.0 | 61 | 1.0 | ||
>47.9 | 107 | 1.090 (0.770 to 1.542) | 65 | 1.109 (0.628 to 1.959) | ||
Sex | 0.045 | 0.558 | ||||
Male | 174 | 1.650 (1.012 to 2.688) | 109 | 1.293 (0.548 to 3.052) | ||
Female | 38 | 1.0 | 17 | 1.0 | ||
Hepatitis history | 0.810 | 0.991 | ||||
Yes | 164 | 1.053 (0.692 to 1.602) | 107 | 1.004 (0.450 to 2.240) | ||
No | 48 | 1.0 | 19 | 1.0 | ||
AFP (ng/ml) | 0.000 | 0.000 | ||||
≤20 | 67 | 1.0 | 56 | 1.0 | ||
>20 | 145 | 2.262 (1.490 to 3.434) | 70 | 5.305 (2.826 to 9.958) | ||
Liver cirrhosis | 0.891 | 0.983 | ||||
Yes | 132 | 0.975 (0.682 to 1.395) | 88 | 1.0 | ||
No | 80 | 1.0 | 38 | 0.993 (0.539 to 1.831) | ||
Tumour size (cm) | 0.000 | 0.000 | ||||
≤5 | 59 | 1.0 | 76 | 1.0 | ||
>5 | 153 | 6.295 (3.688 to 10.747) | 50 | 2.839 (1.586 to 5.082) | ||
Tumour multiplicity | 0.000 | 0.000 | ||||
Single | 128 | 1.0 | 87 | 1.0 | ||
Multiple | 84 | 3.480 (2.429 to 4.987) | 39 | 3.672 (2.065 to 6.529) | ||
Differentiation | 0.021 | 0.102 | ||||
Well-moderate | 153 | 1.0 | 87 | 1.0 | ||
Poor-undifferentiated | 59 | 1.534 (1.068 to 2.203) | 39 | 1.630 (0.908 to 2.927) | ||
Stage | 0.000 | 0.000 | ||||
I–II | 88 | 1.0 | 62 | 1.0 | ||
III–IV | 124 | 5.393 (3.525 to 8.252) | 64 | 5.400 (2.526 to 11.542) | ||
Vascular invasion | 0.000 | 0.000 | ||||
Yes | 108 | 4.923 (3.310 to 7.322) | 57 | 5.362 (2.724 to 10.553) | ||
No | 104 | 1.0 | 69 | 1.0 | ||
Relapse | 0.000 | 0.000 | ||||
Yes | 105 | 1.907 (1.330 to 2.734) | 43 | 2.860 (1.600 to 5.112) | ||
No | 107 | 1.0 | 83 | 1.0 | ||
EZH2 | 0.001 | 0.009 | ||||
Negative expression | 26 | 1.0 | 16 | 1.0 | ||
Positive expression | 186 | 3.506 (1.703 to 7.219) | 110 | 5.451 (1.318 to 22.543) |